Is Catalyst Pharmaceuticals, Inc. (CPRX) a Buy, Sell, or Hold?
NASDAQ : CPRX
Catalyst Pharmaceuticals, Inc.
$31.49 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 3.01M
- Market Capitalization
- $3.85B
- P/E Ratio
- 17.49
- Dividend Yield
- 0.00%
- Price Target
- $31.75
- Year High
- $32.56
- Year Low
- $19.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.10
Company Overview
NASDAQ
Richard John Daly
Biotechnology
Healthcare
CPRX
182
US
USD
Liquidity Metrics
0.00
7.10
6.84
5.71
0.00
Sales & Valuation
$588.99M
6.46
3.80
18.52
1.70
Profitability
$1.68
$214.33M
37.08%
49.66%
23.65%
19.29%
P/E Metrics
17.49
2.07
2.07
Analyst Price Target & Rating
$31.75
$32.00
$31.50
0/5
16 Analysts
-0.82%
Financial Health Scores
20.00
4/9
$807.99M
$1.15B
$134.91M
$296.46M
Key Metrics (TTM)
$3.1B
5.20
9.27
7.10
23.65%
19.67%
5.75%
5.40%
$18.37
176 days
Company Executives
| Name | Title |
|---|---|
| Gregg Russo | Chief Human Resources Officer |
| Steven R. Miller | Executive Vice President, Chief Operating Officer & Chief Scientific Officer |
| William T. Andrews FACP | Chief Medical Officer |
| Mary Coleman | Vice President & Head of Investor Relations |
| Richard John Daly | President, Chief Executive Officer & Director |
| Michael W. Kalb | Executive Vice President, Treasurer & Chief Financial Officer |
| Preethi Sundaram | Chief Strategy Officer |
| Jeffrey Del Carmen | Executive Vice President & Chief Commercial Officer |
| Brian Elsbernd | Chief Compliance Officer & Chief Legal Officer |
| Patrick J. McEnany | Co-Founder & Non-Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gra ... vis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
2026-07-16 05:06:45
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
2026-07-16 03:36:00
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
2026-07-10 06:03:39
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
2026-07-02 10:36:08
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
2026-06-30 08:03:00
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
2026-06-25 13:00:00
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
2026-06-24 15:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-06-24 14:38:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.
Frequently Asked Questions
-
What is the current Catalyst Pharmaceuticals, Inc. (CPRX) stock price?
-
Catalyst Pharmaceuticals, Inc.(NASDAQ:CPRX) stock price is $31.49 in the last trading session. During the trading session, CPRX stock reached the peak price of $32.56 while $19.05 was the lowest point it dropped to. The percentage change in CPRX stock occurred in the recent session was 0.0% while the dollar amount for the price change in CPRX stock was $0.
-
CPRX's industry and sector of operation?
-
The NASDAQ listed CPRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CPRX?
-
Gregg Russo | Chief Human Resources Officer
Steven R. Miller | Executive Vice President, Chief Operating Officer & Chief Scientific Officer
William T. Andrews FACP | Chief Medical Officer
Mary Coleman | Vice President & Head of Investor Relations
Richard John Daly | President, Chief Executive Officer & Director -
How many employees does CPRX have?
-
Number of CPRX employees currently stands at 182. CPRX operates from 355 Alhambra Circle, Coral Gables, FL 33134, US.
-
Link for CPRX official website?
-
Official Website of CPRX is: https://www.catalystpharma.com
-
How do I contact CPRX?
-
CPRX could be contacted at phone #305 420 3200 and can also be accessed through its website. CPRX operates from 355 Alhambra Circle, Coral Gables, FL 33134, US.
-
How many shares of CPRX are traded daily?
-
The average number of CPRX shares traded daily for last 3 months was 3.01M.
-
What is the market cap of CPRX currently?
-
The market value of CPRX currently stands at $3.85B with its latest stock price at $31.49